Retrieve available abstracts of 11 articles: HTML format
Single Articles
June 2025
MCCLELLAND S 3RD, Fleming-Hall E, Smith TK, Onyewadume L, et al Establishing Feasibility of the Navigator-assisted Hypofractionation (NAVAH)
Program to Address Radiation Therapy Access Disparities Facing African-Americans
With Prostate Cancer.
Am J Clin Oncol. 2025;48:325-326. PubMed
CARMELI Y, Shpatz Y, Oren-Ivry I, Mansano A, et al Effect of Continuous Nutritionist-led Guidance on Bowel Preparation in Patients
Undergoing Prostate Stereotactic Body Radiation Treatment With Endorectal
Spacing: A Prospective Pilot Trial.
Am J Clin Oncol. 2025;48:314-318. PubMedAbstract available
May 2025
SABBAH A, Delouya G, Laskine M, Taussky D, et al Metabolic Plasticity in Prostate Cancer: The Warburg Effect and Its Clinical
Relevance.
Am J Clin Oncol. 2025 May 15. doi: 10.1097/COC.0000000000001215. PubMedAbstract available
January 2025
SMITH RP, Mohammed MA, Beriwal S, Benoit RM, et al Prostate Brachytherapy With Cs-131: Long-term Results Compared With Published
Stereotactic Body Radiotherapy Data.
Am J Clin Oncol. 2025;48:34-37. PubMedAbstract available
November 2024
QURESHI Z, Fatima E, Safi A, Khanzada M, et al Talazoparib for the Treatment of Metastatic Castration-resistant Prostate Cancer:
A Narrative Review.
Am J Clin Oncol. 2024 Nov 25. doi: 10.1097/COC.0000000000001159. PubMedAbstract available
October 2024
OHAEGBULAM KC, Post CM, Farris PE, Garzotto M, et al Safety and Efficacy of Neoadjuvant Docetaxel and Radiotherapy in Localized
High-Risk Prostate Cancer: Results From a Prospective Pilot Study.
Am J Clin Oncol. 2024 Oct 30. doi: 10.1097/COC.0000000000001151. PubMedAbstract available
September 2024
RITTER AR, Prasad RN, Jhawar SR, Bazan JG, et al Hypofractionated Radiation Therapy: A Cross-sectional Survey Study of US
Radiation Oncologists.
Am J Clin Oncol. 2024;47:434-438. PubMedAbstract available
August 2024
MELLGARD G, Saffran N, Chakrani Z, McCroskery S, et al Performance Status and End-of-Life Outcomes in Patients With Metastatic
Castration-resistant Prostate Cancer Treated With Androgen Receptor Targeted
Therapy.
Am J Clin Oncol. 2024 Aug 1. doi: 10.1097/COC.0000000000001115. PubMedAbstract available
July 2024
LEHRER S, Rheinstein PH Salbutamol, a Short Acting Beta-2 Agonist, Reduces Risk and Improves Prognosis of
Prostate Cancer.
Am J Clin Oncol. 2024 Jul 8. doi: 10.1097/COC.0000000000001134. PubMedAbstract available
February 2024
CHAKRANI Z, Mellgard G, Saffran N, McCroskery S, et al Risk Factors for Early Treatment Discontinuation Due to Toxicity Among Patients
With Metastatic Castration-resistant Prostate Cancer Receiving Androgen
Receptor-targeted Therapy.
Am J Clin Oncol. 2024 Feb 12. doi: 10.1097/COC.0000000000001087. PubMedAbstract available
January 2024
JANOPAUL-NAYLOR JR, Koo A, Qian DC, McCall NS, et al Physician Assessment of ChatGPT and Bing Answers to American Cancer Society's
Questions to Ask About Your Cancer.
Am J Clin Oncol. 2024;47:17-21. PubMedAbstract available